Limited Offer
Translational Bioinformatics
- 1st Edition, Volume 139 - March 6, 2024
- Editors: Vijay Kumar Prajapati, Rossen Donev
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 9 3 4 8 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 9 3 4 9 - 1
Translational Bioinformatics is an emerging field in the direction of biomedical research. High throughput technologies can be applied to the generated biological data to develop… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTranslational Bioinformatics is an emerging field in the direction of biomedical research. High throughput technologies can be applied to the generated biological data to develop the vaccine and personalized medicine. This volume consists of the chapters from different stalwart of the field covering the topics such as drug development, vector engineering, vaccine development and translational genomics. Chapters covered in this volume discuss the translational research related with cancer, Alzheimer disease and cardiovascular diseases. This volume includes the chapter describing the importance of computational resources and chemoinformatics for the translational health research. How Omics studies are helping to translate the laboratory data into the development of tools which are beneficial in the clinics have been described. How translational bioinformatics helpful in plant genomics to improve the crops have also been included in this volume. This volume has a chapter which describes the secrets of resistance development and further how these resistance are associated with human infectious diseases. This volume will be useful to the early career researcher in the development of research idea and develop their methodologies in the direction of bioinformatics and it will also give the insight to translate their findings.
- Translational Bioinformatics
- Health Informatics
- Multi-omics
Biochemists, biophysicists, cell biologists, protein chemists, structural geneticists, and structural biologists
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: From genome to clinic: The power of translational bioinformatics in improving human health
- Abstract
- 1 Introduction
- 2 Data sources and methods used in translational bioinformatics
- 3 Impact of translational bioinformatics on human health
- 4 Methods in network biology for the study of complex diseases
- 5 Challenges and limitations of translational bioinformatics
- 6 Future of translational bioinformatics and its potential impact on medicine and human health
- 7 Conclusion
- References
- Chapter Two: Computational resources and chemoinformatics for translational health research
- Abstract
- 1 Introduction
- 2 Overview of chemoinformatics and its applications
- 3 Computational tools and databases for translational health
- 4 Chemoinformatics approaches in translational health
- 5 Translational applications of computational resources and chemoinformatics
- 6 Challenges and future perspectives
- 7 Conclusions
- References
- Chapter Three: Technological advancements in viral vector designing and optimization for therapeutic applications
- Abstract
- 1 Introduction
- 2 In silico approaches for viral vector designing
- 3 Data integration and mining for vector optimization
- 4 High-throughput screening and analysis
- 5 Regulatory considerations and safety assessment
- 6 Translation of viral vector research in clinical practices and future perspectives
- 7 Conclusion
- References
- Chapter Four: A journey from omics to clinicomics in solid cancers: Success stories and challenges
- Abstract
- 1 Introduction
- 2 Multi-omics studies in cancers
- 3 Challenges in integration of multi-omics and clinical data in cancer
- 4 Use of AI and ML in integrating multi-omics and clinical data in cancer research
- 5 Challenges in AI guided clinicomics in cancer research
- 6 Conclusion
- References
- Chapter Five: Computational approaches for identifying disease-causing mutations in proteins
- Abstract
- 1 Introduction
- 2 Databases for disease-causing and neutral mutations
- 3 Features for identifying disease-causing mutations
- 4 Characteristic features of disease-causing mutations
- 5 Identification of disease-causing hotspot residues
- 6 Identification of disease-causing mutations
- 7 Conclusions
- Acknowledgments
- References
- Further reading
- Chapter Six: Uncovering the secrets of resistance: An introduction to computational methods in infectious disease research
- Abstract
- 1 Introduction
- 2 Mechanisms of resistance mutations and development of AMR
- 3 Understanding the implications of resistance mutations and preparative countermeasures
- 4 Experimental methods available to evaluate resistance mutations
- 5 Limitations of the experimental methods to evaluate resistance mutations
- 6 Major computational methods to predict resistance mutations and tackle AMR
- 7 Advantages and limitations of the computational methods to tackle AMR
- 8 ResScan-design protocol and its applications in identifying resistance mutations
- 9 Conclusion
- Acknowledgments
- References
- Chapter Seven: Translational bioinformatics approach to combat cardiovascular disease and cancers
- Abstract
- 1 Introduction
- 2 Omics-based divisions of translational bioinformatics
- 3 Data-security as an issue in translational bioinformatics
- 4 Translational bioinformatics to combat cardiovascular disorders
- 5 Translational bioinformatics to combat cancer
- 6 Future of translational bioinformatics to design treatment strategies beyond CVDs and cancers
- 7 Conclusion
- References
- Chapter Eight: Nanoinformatics based insights into the interaction of blood plasma proteins with carbon based nanomaterials: Implications for biomedical applications
- Abstract
- 1 Introduction
- 2 Study of bio–nano interface via computational simulation
- 3 Interaction of carbon-based nanomaterials with plasma proteins
- 4 Conclusion
- Acknowledgements
- References
- Chapter Nine: cirCodAn: A GHMM-based tool for accurate prediction of coding regions in circRNA
- Abstract
- 1 Introduction
- 2 CircRNA
- 3 CirCodAn
- 4 Conclusion
- Acknowledgment
- References
- Chapter Ten: Recent advances in plant translational genomics for crop improvement
- Abstract
- 1 Introduction
- 2 Role of genomics in crop improvement
- 3 Various approaches in plant translational genomics
- 4 Gene editing technologies in plant translational genomics
- 5 Applications of translational genomics in crop improvement
- 6 Conclusion
- References
- Chapter Eleven: Genome-based solutions for managing mucormycosis
- Abstract
- 1 Introduction
- 2 Material and methods
- 3 Results
- 4 Conclusion
- Acknowledgments
- References
- Chapter Twelve: Protein-protein interaction network analysis for the identification of novel multi-target inhibitors and target miRNAs against Alzheimer’s disease
- Abstract
- 1 Introduction
- 2 Materials and methods
- 3 Results and discussion
- 4 Conclusion and prospects
- References
- Chapter Thirteen: Multiomics data identifies RSPO2 as a prognostic biomarker in human tumors associated with pan-cancer
- Abstract
- Pan-cancer abbreviations
- 1 Introduction
- 2 Methodology
- 3 Survival analysis
- 4 Promoter methylation of RSPO2
- 5 RSPO2 alteration analysis
- 6 RSPO2 expression and its correlations to immune and molecular subtypes
- 7 Correlations between RSPO2 expression and immune infiltration analysis
- 8 Gene Set Cancer Analysis
- 9 Drug sensitivity analysis
- 10 Results
- 11 High RSPO2 expression correlates with decreased patients’ survival
- 12 RSPO2 promoter hypermethylation: an important event in tumor development
- 13 RSPO2 genetic alterations are associated with worse prognosis
- 14 Discussion
- 15 Conclusion
- References
- No. of pages: 520
- Language: English
- Edition: 1
- Volume: 139
- Published: March 6, 2024
- Imprint: Academic Press
- Hardback ISBN: 9780443193484
- eBook ISBN: 9780443193491
VP
Vijay Kumar Prajapati
Dr. Vijay Kumar Prajapati is working as an Associate Professor at Department of Biochemistry, University of Delhi South Campus, New Delhi, India. He has extensive experience on Immunotherapy, antibody engineering and vaccine development for infectious diseases. He has published approx. 100 research articles in the international journal with >10 book chapters with reputed publishers. He is a recipient of prestigious INSA Medal for Young Scientist from Indian National Science Academy (INSA) and Associate from Indian Academy of Sciences, Benguluru. He has published research work in the prestigious journal such as Journal of Infectious Diseases, Clinical Infectious Diseases, Scientific Reports, Medicinal Research Review, Journal of Cellular Physiology etc. His current h-index is 41 with 5243 citations. .
Affiliations and expertise
Assistant Professor, Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Kishangarh, Ajmer, Rajasthan, IndiaRD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UK